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Abstract
Background: Lack of protective antibodies and inefficient cytotoxic responses are characteristics of chronic hepatitis C
infection. A defect in dendritic cell (DC) function has thus been suspected, but this remains a controversial issue.
Methods and Findings: Here we show that monocyte-derived DC (MoDC) from chronically-infected patients can mature in
response to TLR1/2, TLR2/6 or TLR3 ligands. In contrast, when stimulated with the TLR4 ligand LPS, MoDC from patients
show a profound defect in inducing IFNc secretion by allogeneic T cells. This defect is not due to defective phenotypic
maturation or to the presence of HCV-RNA in DC or monocytes but is correlated to reduced IL-12 secretion by DC.
Restoration of DC ability to stimulate IFNc secretion can be obtained by blocking MEK activation in DC, indicating that MEK/
ERK pathway is involved in the Th1 defect of MoDC. Monocytes from HCV patients present increased spontaneous secretion
of cytokines and chemokines, especially MIP-1b. Addition of MIP-1b on healthy monocytes during differentiation results in
DC that have Th1 defect characteristic of MoDC from HCV patients, suggesting that MIP-1b secretion by HCV monocytes
participates in the Th1 defect of DC.
Conclusions: Our data indicate that monocytes from HCV patients are activated in vivo. This interferes with their
differentiation into DC, leading to deficient TLR4 signaling in these cells that are enable to induce a Th1 response. This
specific defect is linked to the activation of the MEK/ERK pathway.
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Introduction
HepatitisCvirus(HCV)isasingle-strandedRNAvirusclassifiedin
the Flaviviridae virus family by sequence homology [1,2]. HCV
infection is a major public health problem since 200 millions people
are infected worldwide. The infection is characterized by a high rate
of progression to chronicity which often leads to hepatic diseases such
as cirrhosis and hepatocellular carcinoma [3]. In chronically infected
patients, HCV often resists to clearance even after repeated antiviral
treatments. Thus, the virus may have evolved strategies to escape the
immune surveillance.
Several groups have reported that monocyte-derived DC
(MoDC) from HCV chronically-infected patients have impaired
allostimulatory capacities [4–11], however this was challenged by
other groups showing that MoDC from chronically-infected
patients could phenotypically and functionally mature [12–14].
Since the patients appear immunologically competent, major
dysfunction of dendritic cells (DC) is not expected, rather a discrete
DC function could be targeted by the virus without affecting global
immunity. Recent studies reported that peripheral blood DC of
chronically infected patients express less IL-12 than control cells
from healthy individuals [15] and a small population of circulating
myeloid DC displayed an impaired response to specific toll-like
receptor (TLR) stimulation [16]. These transmembrane receptors
expressed by cells of innate immunity are involved in the detection
of microbes and activation of signaling pathways inducing the
innate immune response.
There is increasing evidence that viruses can interact with TLR
signaling. Viral components can either bind to TLR and activate
their signaling pathway or block TLR function by interfering with
intracellular intermediates. TLR3 activation can be triggered by
polyriboinosinic-polyribocytidylic acid (poly I:C), a synthetic
analog of double-stranded RNA (dsRNA) generated during viral
replication. Moreover, the HCV serine protease NS3/4A can
specifically degrade the adaptor protein TRIF resulting in
inhibition of TLR3 signaling in HeLa cells [17]. TLR2 is also
involved in the detection of viral components such as measles
hemagglutinin or viruses such as human cytomegalovirus or
PLoS ONE | www.plosone.org 1 May 2008 | Volume 3 | Issue 5 | e2260herpes simplex virus type 1 [18–20]. Although TLR4 is well-
known for its capacity to detect bacterial lipopolysaccharide (LPS),
this receptor can also recognize viral components such as the
fusion protein from respiratory syncytial virus (RSV) [21] and the
envelope protein of mouse mammary tumor virus (MMTV) [22].
TLR4 is important for clearing RSV infection [23] whereas
MMTV maintenance depends on TLR4 stimulation by the virus
that induces immunoregulatory IL-10 secretion [24]. HCV non
structural proteins such as NS5A can interact with MyD88,
inhibiting TLR signaling and reducing cytokine production
resulting from TLR activation in macrophages [25].
We examined the type of T cell response elicited by myeloid DC
derived from blood monocytes after stimulation with different
TLR ligands. Here we show that DC differentiated from
monocytes of patients chronically infected by HCV present an
altered TLR4-induced maturation resulting in a deficient Th1
function that can be restored by inhibition of the MEK-ERK
signaling pathway. The monocytes isolated from these patients
have an increased level of activation and secrete higher amounts of
cytokines and chemokines especially MIP-1 a and b, that can
interfere with DC functional maturation.
Materials and Methods
Patients
Blood samples were obtained from volunteers attending the
Liver Unit at Necker Hospital (Paris, France). Blood was collected
with the written informed consent of the patient during a
therapeutical bleeding prescribed by Pr. S. Pol (Service d’hepa-
tologie, Ho ˆpital Cochin, Paris). Clinical protocols conformed to
ethical guidelines of the authors’ institutions. Chronically-infected
patients have not been given antiviral therapy for more than six
months. Viruses were of genotypes 1a, 1b, 3 and 4a.
Monocyte purification and stimulation
CD14
+ monocytes were purified from peripheral blood of healthy
or chronically-infected individuals mainly as previously described
[26]. PBMC were isolated from human peripheral blood by standard
density gradient centrifugation on Ficoll-Hypaque (GE healthcare,
Uppsala, Sweden), then mononuclear cells were separated from PBL
by centrifugation on a 50 % Percoll solution (GE healthcare).
Monocytes were purified by immunomagnetic depletion (Dynal,
Oslo, Norway), using a cocktail of mAbs anti-CD19 (4G7
hybridoma), anti-CD3 (OKT3, American Type Culture Collection,
Rockville, MD, USA), anti-CD56 (NKH1, Beckman Coulter,
Fullerton, CA, USA) and anti-CD16 (Beckman Coulter). Recovered
m o n o c y t e sw e r em o r et h a n9 0%p u r ea sa s s e s s e db yC D 1 4l a b e l i n g .
Monocytes (10
6 cells/ml) could be stimulated for 24h in complete
RPMI 1640 medium supplemented with 10% FCS, with either
1 mg/ml LPS (E. coli 055:B8, Sigma-Aldrich), 10 mg/ml poly I:C
(pIC; GE healthcare), 10 mg/ml peptidoglycan (PGN; S. Aureus,
Sigma-Aldrich) or 10 mg/ml Pam3CSK4 (Pam; Axxora, San Diego,
CA). Cells were pelleted and supernatants harvested.
HCV-RNA quantification
RNA was extracted from 10
6 monocytes or PBL, using RNeasy
mini kit (Qiagen, Courtaboeuf, France). RNA was eluted in 40 ml
water and stored at -80uC. HCV-RNA quantification was
performed by real-time PCR of the 59 HCV non-coding region
as described previously, but with minor modifications [27,28].
Briefly, RNA (4 ml) was reverse-transcribed with a Thermoscript
reverse transcriptase kit (Gibco-BRL) with the RC21 primer [29].
Real-time PCR was carried out with 2 ml cDNA and the RC1 and
RC21 primers by using an LC FastStart DNA Master SYBR
Green I kit and a LightCycler apparatus (Roche Diagnostics).
DC differentiation and maturation
Purified monocytes (10
6 cells/ml) were differentiated to immature
DC in complete RPMI 1640 medium supplemented with 10% FCS,
50 ng/ml human rGM-CSF and 62.5 ng/ml human rIL-4 (from
AbCys, Paris, France) during 6 days. Maturation was induced at day
5 with LPS (1 mg/ml), PGN (10 mg/ml), Pam (10 mg/ml) or pIC
(10 mg/ml). When indicated, cells were pre-incubated with 40 mM
MEK inhibitor (PD98059; Biomol, Plymouth Meeting, PA, USA) at
day 4, or with 200 ng/ml MIP-1b or 20 ng/ml MIP-1a (R&D
systems, Minneapolis, MN, USA) at day 0. All cells and culture
supernatants were collected at day 6.
Phenotype
Phenotype was analyzed by flow cytometry on a FACSCalibur
(BD Biosciences, Franklin Lakes, NJ) using FITC-conjugated anti-
CD14, -HLA-DR, -CD80, -CD54 and PE-conjugated anti-CD1a,
-CD86, -CD83 and -CD40 (all from Beckman Coulter).
Cytokine assay
Culture supernatants were stored at –80uC. Cytokine concen-
trations were determined using sandwich ELISA specific for
IL12p40 (Biosource, Camarillo, CA, USA), IL-6, TNFa, IL-10
and IL-13 (Endogen, Woburn, MA, USA) or using Cytometric
Bead Array (CBA) inflammation kit or CBA flex (BD biosciences)
for IFNc, IL-5, IP-10, MIP-1a, and MIP-1b.
Mixed Lymphocyte Reaction (MLR)
Allogeneic CD3
+ T cells were purified from non-infected blood
donors as described [26] and primary MLR were conducted in 96-
well flat-bottom culture plates. DC recovered at day 6 were
washed and cocultured with 2610
5 allogeneic T cells at DC/T cell
ratios ranging from 1/10 to 1/40. Culture supernatants were
harvested after 5 d of coculture for IL-5, IL-13 and IFNc assay.
Results
Deficient Th1 function in MoDC from HCV patients upon
LPS stimulation
The capacity of MoDC from chronically-infected patients to
stimulate allogeneic T cells was examined by MLR experiments
and compared to MoDC from healthy blood donors. Allogeneic T
cells from healthy donors were used to assess MoDC ability to
induce a Th1 or Th2 oriented response, upon activation by
different TLR ligands. LPS was used as a prototype of TLR4
ligand, pIC for TLR3 stimulation, and PGN or Pam as ligands of
the heterodimers TLR2/TLR6 or TLR2/TLR1 respectively.
MoDC from chronically-infected patients stimulated with the
TLR4 ligand LPS showed a strongly decreased ability to induce
IFNc secretion by allogeneic T cells compared to MoDC from
healthy individuals (figure 1A). These LPS-treated MoDC were
only slightly more efficient than immature MoDC with a mean
stimulation index of 1.6 compared to 24.3 for MoDC from healthy
donors. This difference between MoDC from HCV and healthy
individuals was statistically highly significant (p,0.01) using the
non parametric Mann-Whitney rank test. No significant increase
in Th2 cytokines such as IL-5 and IL-13 could be detected in
coculture supernatants of T cells with HCV-MoDC compared
with healthy MoDC (data not shown). Maturation of MoDC from
HCV-infected patients stimulated by TLR2/6, TLR2/1 or TLR3
ligands yielded cells able to stimulate IFNc production by T cells
TLR4 Defect in HCV Patients DC
PLoS ONE | www.plosone.org 2 May 2008 | Volume 3 | Issue 5 | e2260Figure 1. Comparison of MoDC from chronically HCV infected patients and healthy individuals upon TLR ligands stimulation. MoDC
from healthy individuals or chronically HCV infected patients were treated at day 5 with LPS, PGN, Pam or pIC for 24h. Control immature DC were
obtained at day 6 without any treatment. (A) DC harvested at day 6 were cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell in
triplicates. IFNc was assayed in coculture supernatants using CBA Flex kit. Stimulation index was determined as the ratio between stimulated DC and
control iDC of the mean IFNc secretion for the triplicate. The Mann-Whitney U test was used to generate p value for comparison of HCV (n=11)
versus healthy (m=17) individuals. The mean stimulation index for both groups is indicated on the graph and median values for healthy donors and
HCV patients were respectively 1.1 and 6.2 with LPS-stimulated DC, 7.2 and 6.0 with PGN-stimulated DC, 8.1 and 7.9 with PAM-stimulated DC and 1.4
and 1.9 with pIC-stimulated DC. (B, C) Phenotypic analysis were performed on DC harvested at day 6 from an healthy donor (B) or an HCV patient (C).
Representative results of one experiment out of eleven. (D, E) Cytokine secretions in DC supernatants harvested at day 6. Mean secretion6SD for
eleven different HCV patients and 10 to 18 healthy donors. * The mean secretion of Mo-DC from HCV patients is lower than that of MoDC from
healthy individuals with p,0.01 in a Student’s test.
doi:10.1371/journal.pone.0002260.g001
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Therefore HCV infection is associated with a selective Th1 defect
of MoDC in the TLR4 pathway. To understand how HCV
infection interferes with TLR4-induced maturation, we analyzed
the phenotype and the cytokine secretion of mature cells.
The expression of characteristic markers of DC maturation was
upregulated on MoDC in response to TLR ligand stimulation
(figure 1B, C). Without any stimulation, MoDC from HCV
chronically-infected patients had the characteristics of immature
DC. In response to TLR ligands, DC maturation resulted in
enhanced expression of costimulation molecules (CD80, CD86,
CD40), MHC class II and adhesion molecules (CD54) with similar
efficiencies whether cells were derived from HCV patients or
healthy donors. Differences in HLA-DR and CD86 expression
levels between healthy and HCV
+ individuals are donor-
dependent (figure S1). Therefore the deficient Th1 function of
LPS stimulated MoDC from HCV patients could not be explained
by altered expression of these surface markers of DC.
The cytokine secretion profile of mature DC participates in the
orientation of the T cell response. Therefore we quantified the
cytokines secreted in the supernatant of DC culture after 24 h
maturation induced by the different TLR ligands. Pam or pIC-
stimulated DC secreted low amounts of IL-6, TNFa, IL-10 and
IL-12 whereas LPS or PGN-activated DC showed strong
secretions of cytokines especially IL-6 and IL-12 (figure 1D, E).
A significant difference could be observed for IL-12 secretion.
Upon LPS stimulation, MoDC from chronically-infected individ-
uals secreted lower amounts of IL-12 than MoDC from healthy
individuals (p,0.01). Thus Th1 disabled function following TLR4
stimulation appeared to be correlated to low IL-12 secretion by
DC derived from HCV patients (figure 2). IFNc secretion induced
by LPS-stimulated MoDC from healthy donors was not correlated
to the amount of secreted IL-12, indicating that in normal MoDC,
IL-12 is not a limiting factor of the induction of the Th1 response.
Th1 defect is not correlated to HCV-RNA content in
monocytes
The presence of HCV-RNA in monocytes of patients has been
previously described and was confirmed by our results. However,
we found a very low level of HCV-RNA in these cells with less
than 4 copies of HCV-RNA for 10
3 monocytes (figure 3A). HCV-
RNA content in PBL was even lower. Moreover we did not
observe any correlation of HCV-RNA content in blood monocytes
with the intensity of the Th1 defect upon LPS stimulation
(figure 3B). After differentiation of monocytes into DC, HCV-
RNA level was extremely low and at the limit of the detection
threshold (data not shown). Therefore, it is very unlikely that the
presence of HCV-RNA in monocytes or in DC could be
responsible for the Th1 defect.
Th1 function can be restored by inhibition of the MEK-
ERK pathway
Since DC differentiation occur in absence of viral components,
monocytes may have been conditioned in HCV patients by
signals affecting their differentiation into mature DC. p38-MAPK
and ERK kinases have been shown to play a role in TLR4
maturation of DC [30–34]. We previously found that the
hyperactivation of ERK pathway could disable the Th1 function
of DC treated by 1-methyl-tryptophan [35]. Therefore the MEK
inhibitor PD98059 (PD) that prevents ERK phosphorylation was
used to analyze the involvement of this pathway in the Th1 defect
of HCV MoDC. These cells were treated at day 4 with PD before
LPS stimulation at day 5. DC harvested at day 6 were washed
and co-cultured with allogeneic T cells and IFNc secretion was
quantified. The results show that blocking the MEK-ERK
pathway in MoDC from HCV chronically-infected patients
restored their ability to induce IFNc secretion by T cells
(figure 4A). The restoration has been observed for 6 out of 7
patients. For patients DC that responded to ERK inhibitor
treatment, the stimulation index for IFNc secretion was increased
by more than 5 fold in mean (figure 4B). These results suggest
that monocytes from HCV patients display an altered ERK
pathway that can interfere with LPS-induced maturation.
Monocytes from HCV patients secrete higher amounts of
cytokines and chemokines
To analyze the activation state of monocytes, we measured their
capacity to secrete cytokines and chemokines without stimulation
Figure 2. Decreased IL-12 secretion by MoDC from HCV-chronically infected patients is correlated to Th1 deficient function. MoDC from
HCV chronically infected patients were treated at day 5 with LPS and harvested at day 6. IL-12p40 was quantified in the supernatants and DC were
cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell. IFNc was measured by CBA in supernatants of cocultures. Stimulation index was
determined as the ratio of mean triplicate value of IFNc induced by LPS stimulated DC compared to control iDC. R
2 is Pearson’s correlation coefficient.
doi:10.1371/journal.pone.0002260.g002
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found any significant difference in the response to TLR ligands of
monocytes from HCV patients compared to those isolated from
healthy individuals (figure 5) as assessed by their similar levels of
secretion of IL-6, IL-1b, TNFa, IL-10, IP-10 and MIP-1a and b.
Especially no defect in the response of HCV-monocytes to TLR4
ligand could be detected. In contrast a difference was observed on
non-stimulated monocytes as their basal level of cytokine and
chemokine secretion was higher for HCV patients than for
healthy individuals (figure 6). The difference is especially
important for MIP-1 a and b, IL-6 and IL-8. The global
increase in all cytokines and chemokines measured, strongly
suggests that monocytes from HCV patients have an elevated
activation state probably resulting from environmental modifi-
cations induced by HCV infection. This increased level of
cytokine secretion may interfere with DC differentiation
resulting in a Th1 defect in their response to LPS.
MIP-1b interferes with monocyte differentiation into DC,
leading to Th1 disabled DC
MIP-1a and b can both stimulate CCR5, resulting in ERK
activation. We analyzed the impact of MIP-1 b that can be
secreted by monocytes on DC differentiation. Monocytes from
healthy individuals were differentiated in DC with GM-CSF and
IL-4 in the presence of 200 ng/ml MIP-1b. DC collected at day 6,
after 24 h maturation with LPS, presented a reduced ability to
induce IFNc secretion by T cells compared to DC differentiated
without MIP-1b (figure 7). This Th1 deficient function of DC
could be partially restored by pre-treatment with the MEK
inhibitor 24 h prior to LPS maturation. A similar tendency was
observed for MIP-1a although data were not statistically
significative (data not shown). These results show that introduction
of MIP-1 at early stage of differentiation of MoDC results in DC
with reduced Th1 function in response to LPS stimulation, a
mechanism involving the MEK/ERK pathway.
Figure 4. ERK inhibition can restore the Th1 function of MoDC from chronically-infected HCV patients stimulated by LPS. MoDC from
healthy individuals or HCV chronically infected patients were treated at day 5 with LPS, 24h after addition of the ERK pathway inhibitor PD. DC
harvested at day 6 were cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell. IFNc was measured by CBA in supernatants of
cocultures. (A) Comparison of MoDC from one healthy donor (filled bars) and one HCV patient (opened bars) in a MLR using the same allogeneic T
cells. IFNc secretion was normalized to 100% for control healthy LPS-treated MoDC. Mean6SD of three independent experiments in triplicates. (B)
Treatment with the ERK inhibitor PD of MoDC from 7 chronically-infected HCV patients before LPS stimulation. Stimulation index was determined as
the ratio of mean triplicate value of IFNc induced by LPS-stimulated DC compared to control iDC. Statistical analysis was performed using the
Student’s test for paired data.
doi:10.1371/journal.pone.0002260.g004
Figure 3. HCV-RNA content in monocytes does not correlate with Th1 defect of MoDC from HCV patients. (A) Quantification by RT-PCR
of the positive strand of HCV-RNA extracted from 10
6 monocytes or PBL from 11 distinct HCV chronically infected patients. RNA extraction was
realized in triplicate and the mean value of three quantifications is shown. (B) HCV-RNA content in monocytes was plotted against the stimulation
index obtained for each patient. Stimulation index was calculated as the ratio of IFNc secretion by T cells induced by LPS-treated DC compared to iDC
in allogeneic MLR experiments realized as described in figure 1A. HCV-RNA in monocytes and the stimulation index are not linearly correlated with a
Pearson correlation coefficient R
2 close to zero.
doi:10.1371/journal.pone.0002260.g003
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In this paper, we observed that MoDC from HCV chronically
infected patients presented a defective ability to stimulate IFNc
secretion by T cells upon LPS maturation. The allostimulatory
defect was observed only when DC were stimulated with the
TLR4 ligand LPS and not with TLR3, TLR2/6 or TLR1/2
ligands. A growing list of molecules from bacteria, viruses, and
parasites can interfere with TLR4 signaling. This underlines the
crucial role of TLR4 pathway in the innate recognition of
pathogens but may also reveal microbial strategies evolved to
facilitate infection. Physiological relevance of TLR4 signaling
interference by HCV may relate to liver and intestine infection
[36,37]. The liver lies directly downstream of the gut and is
therefore constantly exposed to antigens and microbial products
derived from the intestine. The control of liver inflammation and
Figure 5. Cytokine and chemokine secretions of monocytes. Monocytes were isolated from HCV chronically-infected patients (A, C, E) or
healthy individuals (B, D, F). They were incubated for 24h in the presence or not (control) of TLR ligands. Cytokines (A–D) and chemokines (E, F) were
measured in the supernatants using CBA inflammation kit for IL-6, TNFa, IL-1b and IL-10 and specific CBA Flex kits for IP-10, MIP-1a and MIP-1b. Mean
secretion6SD for five different HCV patients and healthy donors is shown.
doi:10.1371/journal.pone.0002260.g005
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bacteria) is likely to rely, at least in part, on functional
characteristics of hepatic and intestinal antigen presenting cells.
One of these characteristics is the modulation of TLR4 signaling
under the dual pressure of protecting the host from pathogenic
infections and coexistence with the myriad commensal organisms
[38].
There are several reasons for HCV to interfere preferentially
with the TLR4 pathway. This could first reflect the action of LVP
on monocytes. HCV can circulate in the blood of chronically
infected patients in the form of Lipo-Viro-Particles (LVP)
[27,37,39–41]. These particles are triglyceride-rich lipoproteins,
containing viral RNA and capsids and carrying the viral envelope
proteins at their surface. LVP are found in all chronically infected
patients and can represent a variable proportion of the total viral
load ranging from a few percent to 90 percent. They originate
from both the liver and the intestine [37]. We previously reported
that LVP can interfere with TLR4-triggered maturation of DC,
resulting in cells having a better potential to stimulate a Th2
response rather than a Th1 response of T cells. This shift of DC
function did not occur upon pIC stimulation and was found to be
dependent on ERK and p-38-MAPK activation [34]. Although
MoDC from HCV patients did not acquire a Th2 function, one
intriguing possibility is that LVP could interact with blood
monocytes and modify their capacities to differentiate into DC.
The impact of LVP on blood monocytes remains to be analyzed
but it could be mediated either by the viral material carried by the
particle or by its lipid contain. It was previously shown that HCV
E2 envelope protein can induce ERK and p-38-MAPK signaling
in human T cells via both CD81 and Low-Density Lipoprotein
Receptor [42]. LVP could also contain modified lipids that could
activate ERK or alter lipid raft distribution, thus inhibiting
subsequent LPS maturation of DC ex vivo [43–46]. It has been
shown recently that lipoproteins from HCV patients induced some
modifications of lipid synthesis in human monocyte-derived
macrophages [47]. LVP could thus interfere with TLR4 signaling
by modifying the lipid composition of the plasma membrane of
monocytes. Among other possibilities, the induction of Th1
responses can be inhibited by polyunsaturated fatty acids (PUFA),
possibly by insertion in the membrane [48]. PUFA are known to
be agonists of PPARc and we have previously shown that
activating PPARc in DC can inhibit their functional maturation,
leading to phenotypically mature DC unable to induce a Th1
response of T cells [49].
In MoDC from HCV patients, TLR4 signaling remains
functional since the ability of DC to induce IFNc secretion by T
cells can be restored by treatment with the MEK inhibitor 24 h
prior to LPS maturation. The RAS/MEK/ERK pathway is
involved in the regulation of differentiation in many cell types.
However, the function of this pathway depends on the cell type,
the differentiation stage of the cell and the type of stimulation of
the receptor. Interestingly, ERK phosphorylation is involved in the
Figure 6. Cytokine or chemokine secretion by non-stimulated monocytes. Monocytes were isolated from HCV chronically-infected patients
or healthy individuals. They were incubated for 24h in culture medium. Cytokines and chemokines were measured in the supernatants using CBA
inflammation kit and specific CBA Flex kits respectively. Individual secretion values for five different HCV patients and healthy donors are shown by
circles and the mean secretion is marked by the line. Statistical analysis was performed using the Student’s test.
doi:10.1371/journal.pone.0002260.g006
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previously observed that an increased phosphorylation of p38 and
ERK MAP-kinases and a sustained activation of the transcription
factor c-Fos were correlated to a Th2 shift of DC function [35]. In
this model of functional shift induced by 1-methyl-tryptophan, we
found that ERK inhibition could restore the ability of DC to
stimulate IFNc secretion by T cells. This was also the case for DC
generated from HCV patients as shown here. This result strongly
suggests that monocytes isolated from the blood of these patients
present some modifications resulting in a deregulation of ERK
phosphorylation. This dysfunction can be due either to a positive
stimulation of the MEK/ERK pathway or to the absence of
negative regulation by phosphatases such as the dual-specific
phosphatases (DUSP) that oppose the action of MEK by
dephosphorylating ERK. This latter mechanism has been
observed for TLR4-induced plasma cell differentiation [50].
The deficient response to LPS stimulation of MoDC points at
an alteration of the monocytes isolated from HCV patients. This
defect is not correlated to the amount of HCV-RNA detected in
monocytes. The low content of viral RNA in these cells (less than 4
copies for 10
3 cells) is in favor of a role of environmental factors
affecting monocytes function. No or trace amounts of HCV-RNA
remained in differentiated DC indicating that they probably did
not present HCV peptides. In consequence, these cells should not
specifically display an HCV-specific defect in term of antigen
presentation and activation of HCV-specific T cells. We also found
that the addition of IFNa 24h prior induction of maturation by
LPS slightly improved the ability of DC differentiated from
monocytes of 4 out of 6 HCV infected patients, to stimulate IFNc
secretion by T cells (data not shown). This weak restoration of the
TLR4 stimulation efficiency is thus independent of the antiviral
effect of IFNa and probably relate to signaling events triggered by
IFNa.
Monocytes from HCV patients can respond to LPS stimulation,
secreting cytokines and chemokines with an efficiency similar to
that of control monocytes. Desensitization of these cells to LPS can
therefore be excluded. However, we observed that monocytes
from HCV patients had an elevated basal activation state
compared to monocytes from healthy donors. HCV-monocytes
secreted higher levels of cytokines and chemokines among which,
MIP-1 a and b. DC differentiated from healthy monocytes in the
presence of MIP-1b, displayed a similar Th1 defect after LPS
stimulation than MoDC from HCV patients. This defect could be
overcome by inhibition of the ERK pathway. Addition of anti-
MIP-1 antibodies during differentiation of MoDC from HCV
patients tend to restore the ability of these cells to stimulate a Th1
response (Figure S2). The MIP-1 a and b chemokines are found in
higher amounts in the blood of HCV patients [51] and can both
stimulate the CCR5 receptor. Although the mechanism involving
the ERK pathway remains to be determined, ERK hyperactiva-
tion could result from CCR5 stimulation by MIP-1 as it was
previously described for human macrophages [52]. Increased
MIP-1 secretion by HCV monocytes may thus interfere with DC
differentiation in vivo.
Several recent papers also described Th1 deficient functions of
circulating myeloid DC in specific conditions depending on the
activation pathway of DC [8,16,53]. Recently, it has been shown
that the core protein of HCV can inhibit the Th1 function of
monocytes-derived DC via interaction with gC1q receptor [54].
LPS-stimulated MoDC from HCV patients showed a mature
phenotype but a significant decrease of IL-12 secretion that could
participate to the Th1 defect since the intensity of the Th1 defect
was correlated to the intensity of IL-12 decrease. This selective
defect of MoDC derived from chronically-infected HCV patients
is in agreement with the absence of immunodeficiency and is in
line with the study by Rodrigue-Gervais et al. showing deficient
response to LPS of circulating DC ex-vivo [16]. A deficient
secretion of IL-12 was also reported for circulating DC from HCV
patients ex-vivo [6,16].
By acting on TLR4 pathway, HCV may thus exploit a natural
protective mechanism of the liver and the intestine normally used
to control inflammation and immunity to commensal microor-
ganisms.
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Figure 7. MIP-1b interfere with monocyte differentiation into
DC. Monocytes isolated from an healthy individual were differentiated
into DC in presence or not of 200 ng/ml MIP-1b. When indicated,
monocytes were treated with the MEK inhibitor (PD) at day 4 and
maturation was induced by LPS at day 5. Cells harvested at day 6, were
cocultured for 5 days with allogeneic T cells at a ratio of 1/10 DC/T cell
in triplicates. IFNc was measured by CBA in supernatant of cocultures.
Mean IFNc secretion6SD of triplicate wells is shown. * The mean IFNc
secretion stimulated by Mo-DC treated with MIP-1b and LPS is
significantly reduced compared to that of MoDC treated with LPS with
p,0.05 in a Student’s test.
doi:10.1371/journal.pone.0002260.g007
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